Health
EMED PROVIDES ACCESS TO FDA-APPROVED WEGOVY® PILL THROUGH ITS TRUSTED, CLINICALLY GUIDED MODEL OF CARE
eMed Population Health, the leading digital health platform for GLP-1/GIP population health management, today announced it has been named a Novocare Recognized Care Provider delivering access to the newly FDA-approved Wegovy® pill, the first and only oral GLP-1 medication approved for chronic weight management in adults. As a clinically guided platform designed for long-term weight health, eMed continues to reinforce its role as a trusted leader in responsible GLP-1 access, providing structure a
About this update from Novo Nordisk A/s Class B
[{"type":"text","content":"Novo Nordisk names eMed a Novocare® Recognized Care Provider for first and only oral GLP-1 for weight loss","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"MIAMI, Jan. 6, 2026 /PRNewswire/ -- eMed Population Health, the leading digital health platform for GLP-1/GIP population health management, today announced it has been named a Novocare Recognized Care Provider delivering access to the newly FDA-approved Wegovy® pill, the first and only oral GLP-1 medication approved for chronic weight management in adults. As a clinically guided platform designed for long-term weight health, eMed continues to reinforce its role as a trusted leader in responsible GLP-1 access, providing structure and adherence in a market often defined by inconsistent results.","length":599,"tagName":"p"},{"type":"image","alt":"eMed Population Health","displaySize":"","headline":null,"caption":"eMed Population Health","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":309,"url":"https://media.zenfs.com/en/prnewswire.com/5c12efa3d0c4af0e35534879bd5dbf29"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8aiQjENImyoCXL3C0vmZVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU0NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/5c12efa3d0c4af0e35534879bd5dbf29","width":400,"height":309}},"href":"https://mma.prnewswire.com/media/2855632/eMed_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Approved by the U.S. Food and Drug Administration in December 2025, Wegovy® pill (oral semaglutide) is a once-daily pill option for people living with obesity or overweight. Through this collaboration with Novo Nordisk, eMed will deliver access to Wegovy® pill within its clinically guided model of care designed to ensure appropriate use, consistent support, and long-term engagement.","length":385,"tagName":"p"},{"type":"text","content":""GLP-1s are redefining health but too often, people are handed powerful medications without the structure, accountability, and medical support they deserve," said Linda Yaccarino, CEO of eMed. "eMed exists to change that. We deliver GLP-1s the way they were meant to be delivered—through a program designed to drive real, lasting outcomes. Being recognized by Novo Nordisk reinforces what we believe at our core: GLP-1s work best when care, structure, and...